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It is estimated that 2–3% of children in the US have hypertension (HTN) and 8% of chil-
dren ages 4–17 carry the diagnosis of attention-deficit hyperactivity disorder (ADHD). The
prevalence of HTN and cardiovascular (CV) risk factors in children with ADHD on CNS
stimulant treatment (stimulants) compared to no treatment and compared to their healthy
counterparts is not well described. Using National Health and Nutrition Survey data, we
examined demographic, blood pressure (BP) and CV risk factors of 4,907 children aged
12–18 years with and without the diagnosis of ADHD, and further examined the CV risk in
a subgroup of ADHD patients on stimulants. Three hundred eighty-three (10.7%) children
were reported to have ADHD, of whom 111 (3.4%) were on stimulants. Children with ADHD
on stimulants were significantly younger, male, and white compared to those with ADHD
not on medication and those without ADHD. Body mass index (BMI), eGFR, cholesterol,
the prevalence of albuminuria, and poverty were not significantly different between the
three groups. One hundred sixty (2.7%) had BP in the hypertensive and 637 (12.4%) in
the pre-hypertensive range. The prevalence of elevated BP (HTN and/or pre-HTN range)
was not different between children with ADHD on stimulants compared to ADHD without
medication and those without ADHD. Heart rate (HR) was significantly higher in the ADHD
group on stimulants vs. the groups ADHD on no stimulants and without ADHD. When the
relationship between stimulants and the risk of abnormal BP was examined, there was
a significant interaction between having BP in the HTN range and sex. After adjusting for
BMI, race, and age, females with ADHD on stimulants tended to be older and had sig-
nificantly more BP in the hypertensive range. On the other hand, males were more likely
to be of a white race and older, but not hypertensive. Children with ADHD on stimulants
have significantly higher HR than children with ADHD on no stimulants and children with-
out ADHD. On the other hand, the prevalence of abnormal BP classification is comparable
between the three groups.
Keywords: hypertension, heart rate, pediatrics, attention-deficit hyperactivity disorder, NHANES, central nervous
system stimulants
INTRODUCTION
Hypertension (HTN) in children and adolescents has been associ-
ated with target organ damage. It has been reported that as many
as 34–38% of young adults with mild blood pressure (BP) eleva-
tion demonstrate left ventricular hypertrophy, which is the most
common manifestation of target organ damage in childhood and
adolescent HTN. Other associated comorbidities include retinopa-
thy, cognitive impairment, and decreased glomerular filtration
rate (GFR) and atherosclerotic plaques in the aorta and carotid
arteries (1–4).
Centers for Diseases Control and Prevention (CDC) analysis of
data from the 2007 National Survey of Children’s Health (NSCH)
(5) found 9.5% of US children aged 4–17 years ever been diagnosed
with attention-deficit hyperactivity disorder (ADHD), represent-
ing 5.4 million children in the US. Furthermore, ADHD diagnosis
was two times more prevalent among males than females. Approx-
imately 66.3% of children were reported to be taking medication
for the disorder, with the highest prevalence of medication treat-
ment among males aged 11–14 years. It should be noted that the
prevalence of ADHD in children increased from 7.8% in 2003 to
9.8% in 2007 – a 21.8% increase in 4 years (5).
Stimulants are the mainstay of ADHD treatment. The effective-
ness of stimulants in treating ADHD has been well documented.
However, in 2006, because of concern over the cardiovascular
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(CV) effects of ADHD stimulants, the Drug Safety and Risk
Management Advisory Committee of the Food and Drug Admin-
istration suggested a “black box” warning on stimulant drugs to
treat ADHD (6).
The prevalence of HTN and other CV risk factors in children
with ADHD on CNS stimulant medication compared to children
with ADHD without CNS stimulant medication and children
without ADHD is not well described. Using data from National
Health and Nutrition Survey (NHANES) 1999–2004, we examined
demographic and CV risk factors in children with and without the
self-reported diagnosis of ADHD. In addition, we examined CV
risk factors in children with ADHD on CNS stimulant medica-
tions. Finally, since differences in prevalence of ADHD, medication
treatment of ADHD, and abnormal BP have been reported by sex,
we tested a hypothesis of an interaction between BP and sex among
children with ADHD on CNS stimulants.
MATERIALS AND METHODS
STUDY POPULATION
Data from NHANES for the years 1999–2004 were analyzed.
NHANES is an ongoing nationally representative cross-sectional
survey of the civilian, non-institutionalized US population that
uses a complex, stratified, and multistage probability design. The
survey is performed by the National Center for Health Statistics
at the CDC and released in 2-year increments. Survey partici-
pants underwent standardized interviews, physical examinations,
and laboratory testing in their homes and at a mobile examina-
tion center (MEC). Height, weight, and BP measurements were
obtained on all NHANES participants aged 12–18 years.
National Health and Nutrition Survey 1999–2004 was approved
by the National Center for Health Statistics Institutional Review
Board. All of the participants 18 years of age provided informed
consent and for those participants under the age of 18 years,
parents/guardians provided informed consent.
Participant use of CNS stimulants was obtained from self-
report. A personal interview was conducted as part of NHANES
protocol and participants were queried on use of prescription
medication during a 1-month period prior to the survey date.
Participants 16 years of age and younger had a proxy respond for
them while those older than 16 years responded for themselves.
STUDY VARIABLES
Demographic variables included in the current study are age
(years), sex, and self-reported race/ethnicity (categorized as
Mexican-American, Black, White, and other). Poverty–income-
ratio (PIR) is a ratio of a family’s income to the poverty threshold
as defined by the US Census Bureau. A PIR ≤1 was defined as
below the poverty threshold by NHANES.
Physical examination measures were obtained in the MEC
according to standardized protocol (7). Three systolic and dias-
tolic BP measurements were obtained for each participant using
a mercury sphygmomanometer. Based on the average of three
BP measurements and using methods similar to those previously
published (8, 9), we classified participants as having BP in the
hypertensive range if BP was ≥95th percentile for age, sex, and
height and BP in the pre-hypertensive range if BP was≥90th per-
centile and <95th percentile for age, sex, and height. A 60 s pulse
[heart rate (HR)] was calculated by multiplying the 30-s resting HR
times two (1). Participants receiving antihypertensive medications
were excluded from this study.
Body mass index (BMI) was calculated as weight in kilograms
divided by height in meters squared (kg/m2). BMI z-scores were
calculated based on 2000 CDC growth charts (10).
Laboratory procedures are described in detail in the NHANES
General Information for Public Files and Laboratory Files (11,
12). High-sensitivity C-reactive protein (CRP) was measured
by latex-enhanced nephelometry. Serum cholesterol levels were
measured on the Beckman Synchron LX20 (Beckman Coulter,
Brea, CA, USA). Urinary albumin levels were measured by using
a solid-phase fluorescent immunoassay. Urinary creatinine lev-
els were measured by using the Jaffe rate reaction with a CX3
analyzer (Beckman ASTRA, Brea, CA, USA). The urinary albu-
min/creatinine ratio (ACR) was calculated as urinary albumin
divided by urinary creatinine. An ACR ≥30 was used to define
albuminuria. Serum creatinine was measured by means of the
modified kinetic Jaffe reaction during the survey period. Because
the Jaffe method is known to overestimate eGFR compared to
current“gold standard,”glomerular filtration rate (eGFR) was esti-
mated using the new Schwartz formula (13), which has a constant
that on average estimates GFR to be lower by 20% compared to the
old formula in the adolescent population. Also, the new Schwartz
formula is close to the Counahan–Barratt formula used in Europe
to estimate GFR.
Attention-deficit hyperactivity disorder was ascertained
through self-report among NHANES participants aged 12–
18 years of age. Participants were asked whether or not they
were ever told by a doctor or health professional that they had
attention-deficit disorder.
STATISTICAL ANALYSIS
Continuous, normally distributed variables are presented as
mean± SD and categorical variables are presented as % (n). p-
Values were calculated by weighted least squares or weighted
logistic regression analyses. Continuous, abnormally distributed
variables are presented as median (25th, 75th percentile). Given
that the prevalence and use of medication for ADHD is more
common among males, we tested the hypothesis that BP (systolic
and diastolic percentile) was influenced by the sex of the ADHD
child. An interaction product term of sex×BP percentile (systolic
and diastolic separately) was entered into two regression models to
represent the interaction. Statistical regression models adjusted for
ADHD (with and without CNS stimulant use), age, BMI z-score,
ethnicity (white vs. non-white), fasting glucose, total cholesterol,
eGFR, CRP, HR, and poverty.
Standard errors for all estimates were obtained with the Taylor-
linearized variance estimation. Six year sample weights were
applied to account for the complex sampling design of NHANES.
This includes unequal probabilities of selection, over-sampling,
and non-response. All statistical tests used a two-tailed α of <0.05
and were run on Stata (SE 11.2; College Station, TX, USA).
RESULTS
Table 1 presents the characteristics of the 4,907 children aged
12–18 years in NHANES 1999–2004 meeting the study inclusion
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Table 1 | Demographic and bio-clinical characteristics of study populationa–c.
ADHD on CNS stimulants ADHD not on CNS stimulants No ADHD Total
3.41% (n=111) 7.34% (n=272) 89.24% (n=4524) n=4,907
Age (years)b 13.99 (2.07) 14.91 (2.34) 14.99 (2.84) 14.95 (2.79)
Sex (male)d 75.93 (85) 72.93 (196) 47.59 (2,163) 50.41 (2,444)
Raced
White 75.38 (49) 75.86 (113) 60.15 (1,101) 61.83 (1263)
Black 7.81 (29) 11.26 (89) 14.34 (1,383) 13.89 (1501)
Mexican-American 5.31 (21) 4.83 (49) 11.49 (1,677) 10.79 (1747)
Other 11.49 (12) 8.05 (21) 14.02 (363) 13.49 (396)
Poverty (yes) 37.34 (47) 47.53 (154) 45.26 (2,696) 45.15 (2,897)
BMI z -score 0.32 (1.46) 0.61 (1.49) 0.57 (1.49) 0.53 (1.50)
Height (cm)c 162.49 (15.19) 167.84 (12.80) 165.35 (14.34) 165.44 (14.38)
Weight (kg)c 58.39 (24.02) 66.77 (24.83) 63.40 (24.60) 63.48 (24.82)
eGFR (ml/min/1.73 m2)b 109.68 (92.85) 108.96 (95.46) 103.29 (110.84) 103.92 (109.32)
ACR (µg/mg)b 7.30 (4.68, 15.44) 6.16 (3.74, 11.65) 6.49 (4.29, 12.59) 6.51 (4.23, 12.59)
CRP (mg/dl) 0.11 (0.26) 0.22 (0.58) 0.16 (0.60) 0.16 (0.59)
Total cholesterol (mg/dl) 156.64 (32.78) 159.54 (37.40) 160.24 (44.17) 160.06 (43.34)
BP classification range
Normotensive 82.64 (91) 84.19 (228) 85.12 (3,791) 84.96 (4110)
Pre-hypertensive 13.79 (16) 13.74 (37) 12.19 (584) 12.36 (637)
Hypertensive 3.57 (4) 2.06 (7) 2.69 (149) 2.67 (160)
Systolic BP percentile 40.87 (31.93) 37.53 (30.70) 38.46 (37.52) 38.48 (36.89)
Diastolic BP percentile 38.78 (33.94) 38.68 (33.02) 41.54 (37.63) 41.23 (37.28)
Pulse (beats/min)b 81.72 (17.03) 76.33 (15.62) 76.76 (17.57) 76.90 (17.54)
aContinuous variables presented as mean±SD and categorical variables presented as % (n). p-Values calculated by weighted chi-square analysis or weighted least
squares with no ADHD as the reference.
bp<0.05 for comparison between ADHD on CNS stimulants and no ADHD.
cp<0.05 for comparison between ADHD not on CNS stimulants and no ADHD.
dp<0.05 for chi-square analysis between ADHD with and without CNS stimulants and no ADHD.
criteria. Since this was a representative sample of the US
population, these children represent nearly 23 million non-
institutionalized US children between the ages of 12–18 years in
the US. Among these, 10.8% (n= 383) had a self-reported diagno-
sis of ADHD; 7.3% (n= 272) were not on ADHD CNS stimulant
medications; and 3.4% (n= 111) were on CNS stimulant medica-
tions. Mean age was 15 years (SD 2.8). Children with ADHD on
CNS stimulant medication were significantly younger, male, and
white (p< 0.05) compared to those with ADHD not on medica-
tion and those without ADHD. HR was significantly higher in chil-
dren with ADHD on CNS stimulants (81.72 beats/min) compared
to children with ADHD and not on stimulants (76.33 beats/min)
and children with no ADHD (76.76 beats/min) (Table 1). BMI
z-score, eGFR, cholesterol, the prevalence of albuminuria, and
poverty were not significantly different between the three groups.
Among the study sample, 2.7% (n= 160) children had a
mean BP in the hypertensive and 12.4% (n= 637) in the pre-
hypertensive range. The prevalence of abnormal BP (hypertensive
and/or pre-hypertensive range) was not significantly different
between children with ADHD on CNS stimulant medication com-
pared to children with ADHD without medication and those
without ADHD. Systolic and diastolic BP percentiles were also
not significantly different between the three groups (Table 1).
In linear regression models with systolic and diastolic BP
percentile (BP percentile for age, sex, and height) as the out-
come, we tested the hypothesis that BP may be influenced by
the sex of the child with ADHD on CNS stimulants. A prod-
uct interaction term of sex× systolic and diastolic BP percentile
was entered into two separate regression models along with the
lower level terms. The interaction terms (sex× systolic BP per-
centile) and (sex× diastolic BP percentile) were statistically sig-
nificant (p< 0.01) in models that included both main effect terms
along with ADHD (with and without CNS stimulant use), age,
BMI z-score, ethnicity (white vs. non-white), fasting glucose, total
cholesterol, eGFR, CRP, HR, and poverty.
Table 2 presents the study population characteristics by sex.
Females with ADHD and on CNS stimulants were significantly
older, shorter in stature, and had a lower ACR than those with-
out ADHD. Conversely, males with ADHD and on CNS stimu-
lants were significantly younger, and had a higher CRP and HR
compared to those without ADHD.
Tables 3 and 4 present results for regression analyses with sys-
tolic and diastolic BP percentile as the outcome stratified by sex.
In each of these models, children with ADHD (with and with-
out the use of CNS stimulants) are compared to those without
ADHD (the reference group). For females, only poverty and eGFR
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Table 2 | Demographic and bio-clinical characteristics of study population among (A) females (n=2,463)a–c and (B) males (n=2,444)a–c.
ADHD on CNS stimulants ADHD not on CNS stimulants No ADHD Total
(A) FEMALES
n=26 n=76 n=2361 n=2,463
Age (years)b 14.95 (2.82) 14.83 (2.40) 13.77 (2.23) 14.93 (2.80)
Race
White 1.19 (12) 2.92 (28) 57.32 (594) 61.62 (634)
Black 0 (3) 0.52 (26) 13.55 (706) 14.13 (735)
Mexican-American 0.15 (8) 0.21 (15) 10.53 (868) 10.90 (891)
Other 0.26 (3) 0.36 (7) 12.94 (193) 13.55 (203)
Poverty (yes) 31.85 (7) 48.21 (44) 46.75 (1417) 46.56 (1468)
BMI z -score 0.91 (0.99) 0.70 (1.31) 0.57 (1.41) 0.59 (1.41)
Height (cm)b 156.21 (9.24) 162.47 (6.92) 161.00 (9.82) 160.98 (9.91)
Weight (kg) 57.14 (17.58) 63.72 (23.45) 60.24 (21.99) 60.33 (22.07)
eGFR (ml/min/1.73 m2) 121.15 (78.45) 87.57 (94.66) 99.37 (106.25) 99.26 (105.51)
ACR (µg/mg)b 7.58 (6.43, 15.44) 8.81 (4.70, 12.78) 7.93 (5.14, 15) 7.94 (5.13, 14.82)
CRP (mg/dl) 0.18 (0.35) 0.27 (0.79) 0.17 (0.62) 0.18 (0.62)
Total cholesterol (mg/dl) 158.46 (23.58) 171.05 (47.89) 161.97 (42.57) 162.28 (42.70)
BP classification ranged
Normotensive 75.43 (31) 94.13 (100) 91.04 (3039) 90.9 (3170)
Pre-hypertensive 11.45 (2) 5.65 (6) 6.21 (214) 6.27 (222)
Hypertensive 13.11 (3) 0.21 (1) 2.76 (104) 2.83 (108)
Systolic BP percentile 46.92 (34.56) 38.71 (29.99) 37.85 (36.08) 38.03 (35.91)
Diastolic BP percentile 44.47 (34.90) 43.99 (31.78) 44.48 (36.66) 44.46 (36.49)
Pulse (beats/min) 82.17 (17.21) 82.78 (16.50) 79.04 (17.13) 79.24 (0.47)
(B) MALES
n=85 n=196 n=2163 n=2,444
Age (years)b 14.06 (2.01) 14.94 (2.32) 15.03 (2.85) 14.97 (2.77)
Raced
White 76.55 (37) 76.98 (85) 59.49 (507) 62.22 (629)
Black 9.08 (26) 10.64 (63) 14.31 (677) 13.65 (766)
Mexican -American 4.12 (13) 4.66 (34) 11.85 (809) 10.69 (856)
Other 10.25 (9) 7.71 (14) 14.36 (170) 13.44 (193)
Poverty (yes) 39.08 (40) 47.28 (110) 43.61 (1,279) 43.77 (1,429)
BMI z -score 0.16 (1.64) 0.58 (1.54) 0.56 (1.58) 0.54 (1.59)
Height (cm)b 164.48 (16.04) 169.83 (13.56) 170.15 (15.33) 169.82 (15.39)
Weight (kg)b 58.79 (25.76) 67.90 (25.17) 66.88 (26.35) 66.57 (26.51)
eGFR (Schwartz) 106.05 (96.74) 116.89 (93.95) 107.60 (115.43) 108.51 (112.48)
ACR 6.81 (3.97, 16.24) 5.14 (3.55, 11.03) 5.33 (3.65, 9.78) 5.38 (3.65, 10.00)
CRP (mg/dl)b 0.90 (0.22) 0.20 (0.48) 0.15 (0.58) 0.15 (0.55)
Total cholesterol (mg/dl) 156.07 (35.25) 155.26 (31.35) 158.33 (45.74) 157.89 (43.73)
BP classification range
Normotensive 84.92 (111) 80.51 (213) 78.6 (2,526) 79.12 (2,850)
Pre-hypertensive 14.53 (15) 16.75 (41) 18.79 (511) 18.35 (567)
Hypertensive 0.54 (5) 2.75 (8) 2.62 (100) 2.53 (113)
Systolic BP percentile 38.95 (30.68) 37.09 (30.93) 39.14 (39.03) 38.92 (37.80)
Diastolic BP percentile 36.98 (33.36) 36.71 (33.12) 38.31 (38.17) 38.07 (37.51)
Pulse (beats/min)b 81.58 (16.97) 73.94 (14.26) 74.25 (17.38) 74.59 (17.25)
aContinuous variables presented as mean±SD and categorical variables presented as % (n). p-Values calculated by weighted chi-square analysis or weighted least
squares with no ADHD as the reference.
bp< 0.05 for comparison between ADHD on CNS stimulants and no ADHD.
cp<0.05 for comparison between ADHD not on CNS stimulants and no ADHD.
dp< 0.05 for chi-square analysis between ADHD with and without CNS stimulants and no ADHD.
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Table 3 | Systolic blood pressure percentile linear regression models
by sex.
Systolic percentile Coefficient 95% Confidence
interval
p-value
FEMALES
ADHD not on CNS stimulant −0.57 −8.23 7.10 0.88
ADHD on CNS stimulant 6.76 −8.33 21.85 0.37
Age (years) −0.27 −1.07 0.53 0.51
BMI z -score 6.64 5.18 8.10 <0.001
White (yes) −1.42 −4.38 1.54 0.34
Glucose (mg/dl) 0.02 −0.18 0.18 0.99
eGFR (ml/min/1.73 m2) 0.02 0.00 0.04 0.03
CRP (mg/dl) 1.63 −1.68 4.93 0.33
Poverty (yes) 3.93 0.75 7.12 0.02
Total cholesterol −0.01 −0.05 0.04 0.76
Pulse (beats/min) 0.23 0.11 0.35 <0.001
MALES
ADHD not on CNS stimulant −1.17 −5.49 3.15 0.59
ADHD on CNS stimulant 2.61 −4.40 9.61 0.46
Age (years) −1.23 −1.89 −0.57 <0.001
BMI z -score 7.19 5.81 8.56 <0.001
White (yes) −5.00 −8.72 −1.30 <0.01
Glucose (mg/dl) 0.10 0.00 0.20 0.05
eGFR (ml/min/1.73 m2) −0.01 −0.03 0.02 0.66
CRP (mg/dl) −1.30 −4.90 2.30 0.47
Poverty (yes) −0.08 −3.73 3.56 0.96
Total cholesterol 0.07 0.03 0.12 <0.01
Pulse (beats/min) −0.01 −0.13 0.12 0.94
are significant predictors of systolic BP percentile while adjusting
for other covariates. Among males, age, BMI percentile, ethnicity
(white), and total cholesterol are significant predictors of sys-
tolic BP percentile while adjusting for other covariates. It is worth
noting that the SBP coefficient for females with ADHD on CNS
stimulants (n= 26) is 2.5 times greater than for males (n= 85);
6.76 compared to 2.61.
For both males and females BMI z-score, eGFR, and HR were
significant predictors of diastolic BP percentile while adjusting
for other covariates. Among females only age was a significant
predictor of diastolic BP percentile.
DISCUSSION
To our knowledge, this is the largest study to examine the effect
of CNS stimulant medication use on BP classification in a study
population representative of the US children and adolescents.
In this study, we report comparable prevalence of elevated BP
(pre-hypertensive and hypertensive range) between patients with
self-reported ADHD vs. no ADHD diagnosis. Also, we report com-
parable prevalence of elevated BP between the ADHD patients on
stimulant medications vs. no medications. HR was significantly
higher in the group on CNS stimulant medications compared to
children with ADHD on no stimulants and no ADHD.
It is important to point out that children with self-reported
ADHD on stimulant medications had a slightly higher systolic
BP percentile, which was not significantly different between the
Table 4 | Diastolic blood pressure percentile linear regression models
by sex.
Diastolic percentile Coefficient 95% Confidence
Interval
p-value
FEMALES
ADHD not on CNS stimulant −0.63 −7.30 6.04 0.85
ADHD on CNS stimulant 0.07 −13.89 14.03 0.99
Age (years) 1.32 0.48 2.15 <0.01
BMI z -score −1.54 −3.01 −0.07 0.04
White (yes) 1.82 −1.21 4.86 0.23
Glucose (mg/dl) 0.05 −0.09 0.19 0.50
eGFR (ml/min/1.73 m2) 0.06 0.03 0.08 <0.001
CRP (mg/dl) −1.46 −3.21 0.30 0.10
Poverty (yes) 2.80 −0.78 6.39 0.12
Total cholesterol 0.02 −0.03 0.07 0.42
Pulse (beats/min) 0.24 0.13 0.35 <0.001
MALES
ADHD not on CNS stimulant −1.84 −7.53 3.85 0.52
ADHD on CNS stimulant −4.03 −9.94 1.87 0.18
Age (years) 0.05 −0.80 0.90 0.91
BMI z -score −2.35 −3.57 −1.13 <0.001
White (yes) −0.36 −3.21 2.48 0.80
Glucose (mg/dl) 0.01 −0.09 0.11 0.86
eGFR (ml/min/1.73 m2) 0.06 0.03 0.08 <0.001
CRP (mg/dl) −1.07 −5.05 2.91 0.59
Poverty (yes) −0.16 −3.07 2.75 0.91
Total cholesterol 0.02 −0.03 0.06 0.47
Pulse (beats/min) 0.27 0.11 0.42 <0.01
groups and did not change BP classification. We also report a sig-
nificant difference in BP classification by sex; females with ADHD
are significantly more hypertensive, while males with ADHD on
CNS stimulants had a significantly higher HR.
Ten percent of this nationally representative sample of 4,907
children had ADHD. One-third of children with ADHD were
on medications, 90% of whom were on CNS stimulants.
Methylphenidate and amphetamine–dextroamphetamine were
the two most commonly used medications.
Our findings are consistent with a meta-analysis of adult studies
examining the relative change in various CV parameters associ-
ated with ADHD treatment modalities, Mick et al. reported that
subjects randomized to CNS stimulant treatment demonstrated
a statistically significant increased resting HR [+5.7 bpm (95%
CI: 3.6, 7.8), p< 0.001] and systolic BP findings [+2.0 mmHg
(95% CI: 0.8, 3.2), p= 0.005] compared with subjects random-
ized to placebo (14). Samuels and colleagues examined the
effect of stimulants on 24-h ambulatory BP in children with
ADHD, in a double-blind, randomized, cross-over trial they
reported elevations in most hemodynamic parameters derived
from ABPM during the active treatment period; overall dias-
tolic BP (69.7 vs. 65.8 mmHg, p= 0.02) and waking diastolic BP
(75.5 vs. 72.3 mmHg, p= 0.03) were significantly higher during
active treatment. Total HR was also significantly higher dur-
ing active treatment (85.5 vs. 79.9 beats/min, p= 0.004) (15). In
a systematic review by Westover and colleagues examining the
www.frontiersin.org September 2014 | Volume 2 | Article 100 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hailpern et al. ADHD BP NHANES children
relationship between stimulant medications and CV events, 10
population-based observational studies were reviewed. Six out of
seven studies in children and adolescents did not show an associa-
tion between stimulant use and adverse CV outcomes. In contrast,
two out of three studies in adults found an association. The authors
concluded that findings of an association between prescription
stimulant use and adverse CV outcomes are mixed. Studies of
children and adolescents suggest that statistical power is limited
in available study populations, and the absolute risk of an event
is low (16).
The duration of CNS stimulant medication effects on CV para-
meters is not well understood, it is possible that these effects are
less prominent with time. Hammerness and colleagues examined
the effects of high doses of extended-release methylphenidate
(OROS MPH) on CV variables in 114 adolescents with ADHD,
they reported small but statistically significant changes in DBP and
HR at 6 weeks, without further increases up to 6 months follow-
up. A small but not statistically significant increase in SBP was
observed at 6 weeks, this increase was statistically significant at
6 months of follow-up (17). It is important to point out that
male and female participant data were combined and analyzed
together in this study, the study did not classify BP or present BP
percentiles and did not comment on change in BP classification
with increased BP. On the other hand, this study demonstrated
a significant increase in HR in the first 6 weeks, which was sus-
tained until the end of the follow-up period; one patient had to
stop the treatment due to intermittent palpitations. Among the
1758 youth enrolled in the Italian ADHD National Registry, statis-
tically significant increases were observed in CV measures: in the
methylphenidate group after 6 months in HR (+2.01, p= 0.01); in
the atomoxetine group after 6 months in diastolic pressure (+1.60,
p= 0.01) and in HR (+2.93, p= 0.001), and after 12 months in HR
(+3.26, p= 0.003) (18).
In adults, high HR has proven to be a strong predictor of CV dis-
ease and a predictor of the development of essential HTN. Whether
HR itself is a risk factor for development of HTN or just a marker
for sympathetic over activation is still a matter of debate (19, 20).
Previous studies showed a small increase in HR and BP mea-
surements. It is important to point out that while children on
CNS stimulant treatment in our study had similar effects, those
small changes in BP measurements did not change BP classification
range between the different groups. On the other hand, it is impor-
tant to remember that the long-term CV effects of elevated resting
HR and the small increases in BP are not well defined in children
and may contribute to an increased future CV risk. Using two
large administrative databases, Schelleman and colleagues com-
pared the rate of severe CV events and death in children who use
attention-deficit/hyperactivity disorder (ADHD) medications vs.
non-users. They found the rate of CV events in exposed children
to be very low and in general no higher than that in unexposed
control subjects. Because of the low number of events, they had
limited ability to rule out relative increases in event rate (11).
We found males with ADHD on CNS stimulants had a lower
BMI and significantly higher CRP levels. While it is well described
that treatment with CNS stimulants can depress growth in hyper-
active children on stimulant drugs (21), the relationship between
CRP levels and CNS stimulant medication treatment is less well
understood. Researchers have described a significant association
between development of Raynaud’s syndrome and therapy with
CNS stimulants used for the treatment of ADHD in a population
of children followed at the rheumatology clinic. In that patient
population, both CRP and ESR were elevated. The authors attrib-
uted the findings to underlying inflammatory disease (22). Others
have reported methylphenidate and dextroamphetamine to induce
peripheral vasculopathy (23, 24).
The relationship between BP and GFR is complicated. In our
study, higher GFR was an independent determinant of systolic BP
in females and diastolic BP in both males and females (Tables 3
and 4). The underlying mechanisms behind this relationship are
unclear, but someone can speculate on possible hemodynamic
changes that may affect the renal blood flow and the glomeru-
lar filtration pressure. With the help of renal auto regulation,
GFR is maintained relatively stable over a wide range of BP in
healthy individuals; it is unclear how CNS stimulants and increased
sympathetic outflow affect this relationship.
Our study is limited by its cross-sectional design and the inabil-
ity to draw any causal relationships. All three BP measures were
taken at one sitting 5 min apart. As such, none of the children
included in the study can be diagnosed truly hypertensive or pre-
hypertensive based on the fourth report recommendations. Rather,
the average of three BP measures here serve as a proxy for BP status
similar to many other published studies (8, 9). Another limitation
of the study is our use of the modified Schwartz formula to esti-
mate GFR, while the formula has not been validated in healthy
children and adolescents, a modified formula uses a constant that
yields an eGFR that is lower by almost 20–30% compared to the
original formula, this allowed correcting for the use of the Jaffe
method to measure serum creatinine that was used during the
survey period. Although patients were queried about medication
usage, being a cross-sectional study, we neither know the dura-
tion of CNS stimulant use nor do we know compliance of use.
There is also a possibility that study subjects have not answered
questions honestly with respect to diagnosis of ADHD. However,
since NHANES is not a survey about ADHD, there should be no
reason for an individual to bias results and not be truthful about
this history. Nonetheless, there is a possibility that some may have
over- or under-reported. Similarly, some may have over- or under-
reported taking medication for ADHD. However, NHAHES asks
that survey participants bring all medication to the mobile exam-
ination and examiners record the medications directly from the
containers brought in from the patient. This would reduce the
likelihood of bias. It is also possible that a child was on a medica-
tion break and this was not reported. After stratifying by sex, the
number of children on CNS stimulant medications with BP in the
hypertensive and pre-hypertensive range was relatively small.
On the other hand, this study has a number of strengths in that
it examines a large pediatric cohort, representative of the US pop-
ulation. Also, in this study, we classified each patient’s BP based
on the average of three measurements obtained during the survey
exam and adjusted for height and sex: normal BP, hypertensive, or
pre-hypertensive range. In this study, we were able to compare a
subgroup of self-reported ADHD patients on CNS stimulants to
a larger group of self-reported ADHD patients on no medications
as well as to healthy counterparts.
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CONCLUSION
Overall, children on CNS stimulants tend to have higher HRs and
slightly higher BP percentiles. The difference in BP percentiles
did not translate into a difference in the prevalence of BP in
the hypertensive and/or pre-hypertensive ranges between chil-
dren with ADHD on stimulant treatment vs. no treatment and
was comparable to children without ADHD. Sex differences in BP
classification may exist in children on CNS stimulant treatment.
These findings as well as the higher CRP levels in males on CNS
stimulants need to be confirmed by future studies. Prescribers of
CNS stimulant medication need to be aware of the potential long-
term adverse effects of these medications and need to weigh the
risk and benefits when starting stimulant treatment.
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